2024 Prediction from Robert E. White Jr.
Robert E. White Jr. is the President of The Doctors Company. He believes "social inflation will affect malpractice insurers."
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Robert E. White Jr. had to say:
“Social inflation occurs when an insurer’s average claim amount grows faster than the overall inflation rate. Over the decade ending in 2021, social inflation has led to losses estimated to be between $2.4 billion and $3.5 billion — 8% to 11% — of all medical malpractice losses incurred by physician- focused insurers. The rapid uptick began in 2019. People are sympathetic to injured patients. Jurors also relate to credible, empathetic medical professionals, but it can be harder to evoke sympathy for a hospital.
As these cost trends continue, medical professional liability carriers may have to increase their rates to keep up with the losses. Therefore, although social inflation hits insurers first, it affects practices’ premiums.”
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
A Conversation with Jeremiah Johnson, Executive Director of PrEP4All
July 25th 2025Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More
